Research

Selected Research

The Propagation of FDA Regulatory Enforcement Through Drug Supply Chains (Job Market Paper)
Abstract: The Food and Drug Administration (FDA) upholds the safety of US drug supply, but persistent shortages and concentration in manufacturing have raised concerns that the agency’s regulatory enforcement actions may disrupt access to essential medicines. I study this trade-off between access and safety by estimating the causal effects of FDA enforcement at upstream drug manufacturing facilities on downstream hospitals and the patients they serve. Linking Medicare claims to newly assembled data on the origin facilities of sterile injectable opioid drugs, I find that enforcement causes substantial production disruptions, reducing volume from the implicated facility by one-third. Yet, responses by other elements of the supply chain provide resilience: hospitals draw on multi-sourced procurement networks to rapidly substitute to alternative suppliers, such that more-exposed hospitals experience no detectable declines in drug supply relative to less-exposed hospitals. Even in high-risk conditions under which supply does decline—among rural hospitals and when enforcement occurs during critical shortages—the disruption does not compromise patient health or quality of care. These findings suggest that, despite concerns about fragility in this setting, FDA enforcement in concentrated supply chains shields patients from drugs produced at non-compliant facilities while maintaining access and quality of care.

How Does Outsourcing Affect Hospital Drug Access and Quality of Care? Evidence from Compounded Sterile Injectables

A Telehealth Post-Emergency Department Transition of Care Program: A Value-Based Innovation that Integrates Emergency Department Visits into the Care Continuum (Published in Western Journal of Emergency Medicine: Link)